SER

Serina Therapeutics, Inc.

Healthcare — PHARMACEUTICAL PREPARATIONS

Valhalla Score —

—

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

📊 Key Statistics

Market Cap$17M

P/E Ratio—

EPS (TTM)—

EPS YoY—

Revenue YoY—

Float—

Short Float %—

Inst. Ownership—

Sector RS—

📈 Fundamentals

ROE—

ROIC—

ROA—

Current Ratio—

Debt/Equity—

Gross Margin—

Net Margin—

Dividend Yield—

Next Earnings—

⚡ Options Summary

Call OI—

Put OI—

P/C Ratio (OI)—

Gamma Environment—

Max Pain—

Call Wall—

Put Wall—

🎯 Analyst Estimates

Consensus Target—

High Target—

Low Target—

Analysts—

Upside/Downside—

📋 Quarterly Financials

Period	Revenue	Rev YoY	EPS	EPS YoY	Gross Margin

Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

Type	Strike	Exp	Size	Premium	Time

Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

Type	Price	Size	Value	Venue	Time

Start Free Trial Full insider & congressional trade history

👤 Insider Trades

Name	Type	Shares	Price	Date

Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

Institution	Shares	Value	% of Class

SER